Description:
The global obesity epidemic continues to accelerate, with prevalence rising worldwide. Obesity is a key driver of cardiovascular risk factors—including dyslipidemia, type 2 diabetes, hypertension, and sleep disorders—and independently contributes to the development of cardiovascular disease (CVD) and related mortality.
In this webinar, we will explore recent advances in drug target discovery for fat loss and muscle preservation, highlighting key pathways such as GLP-1, INHBE, ACVR1C, Activin A Receptor Type 2 (ActRII), and Myostatin. We will also examine emerging therapeutic targets for cardiovascular disease, including Lipoprotein(a), PCSK9, and ANGPTL3.
In addition, we will showcase Biocytogen’s portfolio of humanized mouse models and disease models, designed to accelerate the development of next-generation therapies for metabolic and cardiovascular diseases.
Featured case studies include:
In vivo drug efficacy studies in HFD-induced humanized GIPR, GLP1R, and GCGR mouse models
Muscle preservation studies targeting ActRII and Myostatin
Mouse models for lipid metabolism disorders
In vivo drug efficacy studies in Western diet-induced humanized LPA, APOB, and PCSK9 mouse models
Speaker：
Jinyi Ma, Ph.D
Product Manager
BioMice Product Department
Biocytogen (Beijing) Pharmaceutical Co. Ltd.
Dr. Jinyi Ma received her PhD in Tianjin Medical University majoring in mechanistic study of pyroptosis and the development of single-domain antibody screening. She subsequently joined Biocytogen as a Product Manager in the BioMice Product Department. Dr. Ma manages the development of humanized mouse models for metabolic diseases and small nucleic acid therapeutics. A series of humanized mouse models has been successfully implemented across diverse therapeutic areas, including cardiovascular diseases, obesity, diabetes, and non-alcoholic steatohepatitis (NASH).
